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males), most of them M2 type of FAB classification.
In the other two cases, the diagnosis was refractory
anemia with excess blasts and CML in blast crisis.
Cytogenetically, 54% of AML patients with t(8;21)
had additional chromosome abnormalities, and most
of them were similar to those described in the
literature: sex chromosome loss (38%), del 9q
(12,9%), del 7q(6%) and trisomy 8 (6%).
In three cases, we found different additional cytoge-
netic abnormalities. Using fluorescence in situ hybrid-
ization (FISH), two of these showed in the analysis an
atypical fusion between AML1 and ETO genes.
The first case was a 12-year-old girl. She showed
an additional translocation, t(1;1)(q25;p36). The
patient was transplanted and is in complete remission
after 9 years from diagnosis.
The second case was a 77-year-old man recently
diagnosed. He has a variant of the specific translocation,
involving chromosomes 7, 8 and 21, with loss of critical
region 7q31 and loss of the derivative 8. At this
moment, he is in complete remission.
The third patient, a 17-year-old man, has at diagnosis
the typical translocation t(8;21)(q22;q22). He was
transplanted and relapsed after 4 months with additional
anomalies, del(2)(p23),add(3)(p13)+ mar. FISH analy-
sis at that time showed atypical AML1/ETO rearrange-
ment. The patient died after 2 years from diagnosis.
The prognostic value of the additional uncommon
chromosomes abnormalities associated with this
translocation t(8;21) is under discussion. Further
studies with more patients are needed to determine
the clinical relevance of these anomalies.
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Background: Hypermethylated genomic DNA has
been found to be a common feature in tumoral tissues,
although the prevalence of this modification remains
poorly understood. Hypermethylated in cancer 1
(HIC1) gene is a putative tumor suppressor gene on
chromosome 17p13.3 and epigenetically inactivated
in different cancers.
Methods: In this study, using bisulphite-modifying-
based reverse hybridisation technique, a total of 30
prostate tumour specimens were investigated for
promoter methylation status of tumour suppressor
HIC1, DAPK1, SFRP2, p16 and MGMT genes.
Results: High frequency of promoter hypermethylation
was found in HIC1 (70.9%) and SFRP2 (58.3%) genes
in the tumour samples examined. Tumour specimens
also showed hypermethylated promoter domain for the
DAPK1 and MGMT tumour suppressor genes.
Conclusions: These findings showed that tissue-
specific epigenetic silencing of tumour suppressor
HIC1and SFRP2 genes may play a crucial role in tumour
progression and recurrence in prostate carcinomas.
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Myelodysplastic syndromes (MDS) constitute a hetero-
geneous group of clonal disorders of haematopoietic
stem cell diseases characterised by dysplasia and
ineffective haematopoiesis in one or more of the major
myeloid cell lines. This disease occurs predominantly in
older adults where the median age at diagnosis is
approximately 70 years. The aim of this study was to
evaluate the data from cytogenetic analyses in 425
patients with myelodysplastic syndromes. This popula-
tion was constituted by 212 females and 213 males; the
median age at diagnosis is 66 years. Numerical and
structural chromosomal abnormalities were documented
for each patient and subdivided according to the number
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of additional abnormalities. From the 425 cytogenetic
analyses, 97 (22.8%) were abnormal. The results for the
abnormal population were as follows: 73.2% had only
one anomaly, 9.3% had two anomalies, and 17.5% had a
complex karyotype. In the abnormal population, the
most frequent isolated anomaly observed was the
trisomy 8 (17.5%), followed by the deletion of
chromosome 5 (13.4%), the loss of chromosome Y
(11.3%) and the deletion of chromosome 20 (8.2%).
When associating these anomalies with complex kar-
yotypes, the most frequent anomaly observed was the
deletion of chromosome 5 (24.7%). Overall, these
results are different from those in the literature; however,
the deletion of chromosome 5 is still the most recurrent
anomaly in this syndrome.We can also conclude that the
loss of chromosomeY is not always associated with age,
but is one of the anomalies that characterize this group
of pathologies. All these anomalies were found by
cytogenetic analysis, a low-cost technique that allows
clinicians to use this important prognostic tool to
evaluate and make a more accurate clinical decision
for patients with MDS.
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The clinical association between loss of the Y
(L0Y) chromosome and haematological disorders
has been continuously debated because both
phenomena can be age-related. In order to under-
stand the relationship between the L0Y chromo-
some and the different haematological diseases,
we retrospectively analysed cytogenetic results of
1,241 male patients from 1995 to 2010. Seventy-
eight patients (6.3%) showed L0Y. Of the 78
patients without Y chromosome, 15 (19.2%) had
B cell lymphomas (B lymphomas), 12 (15.4%)
had myelodysplastic syndromes (MDS), 10
(12.8%) had chronic myelogeneous leukaemia
(CML), 10 (12.8%) had acute myeloid leukaemia
(AML), 8 (10.3%) had myeloproliferative neo-
plasms (MN), 6 (7.7%) had chronic lymphocytic
leukaemia (CLL), 5 (6.4%) had multiple myeloma
(MM), 5 (6.4%) had other mature B cell neo-
plasms (BN), 3 (3.8%) had MDS/MN, 3 (3.8%)
had other mature T cell neoplasms (TN), and 1
(1.3%) had acute lymphoblastic leukaemia (ALL).
We did not observe the L0Y chromosome in the
15 patients (1.2% of all patients studied) with
Hodgkin’s disease. These percentages can be
different if we consider only the pathology in
which the L0Y was found: 4.1% of all patients
with MN, 5.7% of all patients with MDS, 9.3% in
the patients with AML, 12.5% in patients with
ALL, 5.8% in patients with CLL, 5.8% in B
lymphoma patients, 8.2% in the CML patients,
4.5% in MM patients, 9.1% in BN patients, 9.1%
in MDS/MN patients and 15.8% in TN patients.
Twenty-five patients (32.1%) had the L0Y associ-
ated with other cytogenetic anomalies. There are
few reports of L0Y associated with haematological
disorders since this has been considered mainly an
age-related event. Therefore, the tendency of L0Y
diseases to be associated that seems apparent in our
data indicates that careful consideration should be
taken when evaluating male patients with L0Y.
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